Literature DB >> 12019122

Determining Linezolid's baseline in vitro activity in Canada using gram-positive clinical isolates collected prior to its national release.

James A Karlowsky1, Laurie J Kelly, Ian A Critchley, Mark E Jones, Clyde Thornsberry, Daniel F Sahm.   

Abstract

All of the isolates of Staphylococcus aureus (n = 317), Enterococcus species (n = 315), Streptococcus pneumoniae (n = 282), and Staphylococcus epidermidis (n = 176) collected at 16 Canadian microbiology laboratories from October 2000 to April 2001 were susceptible to linezolid. Future studies will determine how linezolid clinical use in Canada affects its in vitro activity.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12019122      PMCID： PMC127260          DOI： 10.1128/AAC.46.6.1989-1992.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  25 in total

1.  National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992-April 2000, issued June 2000.

Authors: 
Journal:  Am J Infect Control       Date:  2000-12       Impact factor: 2.918

2.  Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid.

Authors:  R D Gonzales; P C Schreckenberger; M B Graham; S Kelkar; K DenBesten; J P Quinn
Journal:  Lancet       Date:  2001-04-14       Impact factor: 79.321

3.  Surveillance of invasive Streptococcus pneumoniae infection in the province of Quebec, Canada, from 1996 to 1998: serotype distribution, Antimicrobial susceptibility, and clinical characteristics.

Authors:  L P Jetté; G Delage; L Ringuette; R Allard; P De Wals ; F Lamothe; V Loo
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

4.  In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates.

Authors:  E Cercenado; F García-Garrote; E Bouza
Journal:  J Antimicrob Chemother       Date:  2001-01       Impact factor: 5.790

Review 5.  Linezolid.

Authors:  D Clemett; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

6.  Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci.

Authors:  J Prystowsky; F Siddiqui; J Chosay; D L Shinabarger; J Millichap; L R Peterson; G A Noskin
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

7.  In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci.

Authors:  G A Noskin; F Siddiqui; V Stosor; D Hacek; L R Peterson
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

8.  Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis.

Authors:  D F Sahm; J A Karlowsky; L J Kelly; I A Critchley; M E Jones; C Thornsberry; Y Mauriz; J Kahn
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

9.  Resistance mutations in 23 S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center.

Authors:  P Kloss; L Xiong; D L Shinabarger; A S Mankin
Journal:  J Mol Biol       Date:  1999-11-19       Impact factor: 5.469

10.  Oxazolidinone resistance mutations in 23S rRNA of Escherichia coli reveal the central region of domain V as the primary site of drug action.

Authors:  L Xiong; P Kloss; S Douthwaite; N M Andersen; S Swaney; D L Shinabarger; A S Mankin
Journal:  J Bacteriol       Date:  2000-10       Impact factor: 3.490
View more
  1 in total

Review 1.  Linezolid: in infants and children with severe Gram-positive infections.

Authors:  Katherine A Lyseng-Williamson; Karen L Goa
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.